Evidence Supporting Expansion of NCCN Guidelines of Germline Testing in Prostate Cancer
Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.
Samantha E. Greenberg, MS, MPH, CGC, a genetic counselor at the Hunstman Cancer Institute, discusses if the changes to the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.
Overall, Greenberg believe the guideline update is warranted. According to Greenberg, as the NCCN guidelines around testing become broader, it’s important to consider if there is a benefit to that broadening. Some previous research has suggested that metastatic prostate cancer had a higher rate of germline pathogenic variables compared with high-risk groupings.
Greenberg also notes that an analysis found that there is not a large difference in the occurrence of germline mutations between the 2 groups, solidifying the NCCN guideline.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
